Interactions Between Neuropsychiatric Symptoms and Alzheimer's Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline.
Journal
Psychiatric research and clinical practice
ISSN: 2575-5609
Titre abrégé: Psychiatr Res Clin Pract
Pays: United States
ID NLM: 101776485
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
11
2022
revised:
13
12
2022
accepted:
16
12
2022
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
To examine interactions between Neuropsychiatric symptoms (NPS) with Pittsburgh Compound B (PiB) and fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting cognitive trajectories. We conducted a longitudinal study in the setting of the population-based Mayo Clinic Study of Aging in Olmsted County, MN, involving 1581 cognitively unimpaired (CU) persons aged ≥50 years (median age 71.83 years, 54.0% males, 27.5% APOE ɛ4 carriers). NPS at baseline were assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). Brain glucose hypometabolism was defined as a SUVR ≤ 1.47 (measured by FDG-PET) in regions typically affected in Alzheimer's disease. Abnormal cortical amyloid deposition was measured using PiB-PET (SUVR ≥ 1.48). Neuropsychological testing was done approximately every 15 months, and we calculated global and domain-specific (memory, language, attention, and visuospatial skills) cognitive z-scores. We ran linear mixed-effect models to examine the associations and interactions between NPS at baseline and z-scored PiB- and FDG-PET SUVRs in predicting cognitive z-scores adjusted for age, sex, education, and previous cognitive testing. Individuals at the average PiB and without NPS at baseline declined over time on cognitive z-scores. Those with increased PiB at baseline declined faster (two-way interaction), and those with increased PiB and NPS declined even faster (three-way interaction). We observed interactions between time, increased PiB and anxiety or irritability indicating accelerated decline on global z-scores, and between time, increased PiB and several NPS (e.g., agitation) showing faster domain-specific decline, especially on the attention domain. NPS and increased brain amyloid deposition synergistically interact in accelerating global and domain-specific cognitive decline among CU persons at baseline.
Identifiants
pubmed: 36909142
doi: 10.1176/appi.prcp.20220036
pii: RCP21057
pmc: PMC9997077
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4-15Subventions
Organisme : NIA NIH HHS
ID : R33 AG058738
Pays : United States
Informations de copyright
© 2023 The Authors. Psychiatric Research and Clinical Practice published by Wiley Periodicals LLC on behalf of American Psychiatric Association.
Références
Am J Geriatr Psychiatry. 2013 Jul;21(7):685-95
pubmed: 23567400
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Alzheimers Dement. 2013 Sep;9(5):602-8
pubmed: 23562430
JAMA. 2002 Sep 25;288(12):1475-83
pubmed: 12243634
J Comput Assist Tomogr. 1995 Jul-Aug;19(4):541-7
pubmed: 7622680
J Nucl Med. 2009 Jun;50(6):878-86
pubmed: 19443597
Neurobiol Aging. 2011 Jul;32(7):1207-18
pubmed: 19660834
Int J Geriatr Psychiatry. 2021 Sep;36(9):1362-1369
pubmed: 33724517
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Am J Psychiatry. 2018 Jun 1;175(6):530-537
pubmed: 29325447
Aging Ment Health. 2018 Apr;22(4):474-482
pubmed: 28071922
Neurology. 2015 Mar 3;84(9):935-43
pubmed: 25653291
Brain. 2008 Mar;131(Pt 3):665-80
pubmed: 18263627
Int J Geriatr Psychiatry. 2008 Feb;23(2):170-7
pubmed: 17607801
Neuroimage. 2002 Jan;15(1):273-89
pubmed: 11771995
Am J Geriatr Psychiatry. 2016 Nov;24(11):1095-1104
pubmed: 27426238
Alzheimers Dement. 2022 Oct;18(10):1824-1831
pubmed: 34877794
JAMA Netw Open. 2019 Aug 2;2(8):e198964
pubmed: 31397865
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
Arch Neurol. 1991 Jul;48(7):725-8
pubmed: 1859300
Neurology. 2007 Jun 12;68(24):2085-92
pubmed: 17562829
J Neuropsychiatry Clin Neurosci. 2013 Fall;25(4):302-7
pubmed: 24247857
Am J Geriatr Psychiatry. 2021 Feb;29(2):179-191
pubmed: 32646634
Mayo Clin Proc. 2012 Feb;87(2):151-60
pubmed: 22305027
Am J Geriatr Psychiatry. 2020 Jan;28(1):64-71
pubmed: 31186157
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-6
pubmed: 17132964
Am J Psychiatry. 2014 May;171(5):572-81
pubmed: 24700290
J Alzheimers Dis. 2016 Jul 14;53(4):1609-16
pubmed: 27447426
JAMA. 2019 Jun 18;321(23):2316-2325
pubmed: 31211344
Alzheimers Dement. 2010 May;6(3):221-9
pubmed: 20451870
JAMA Psychiatry. 2015 Mar;72(3):284-91
pubmed: 25629787
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Psychol Med. 2010 Jul;40(7):1193-201
pubmed: 19903364
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9
pubmed: 11001602
J Alzheimers Dis. 2015;49(2):387-98
pubmed: 26484900
J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):449-55
pubmed: 24133289
Arch Neurol. 2006 Mar;63(3):435-40
pubmed: 16533972
J Alzheimers Dis. 2010;20(1):175-83
pubmed: 20164594
Neurology. 2017 May 9;88(19):1814-1821
pubmed: 28404803
Arch Gen Psychiatry. 2008 Oct;65(10):1193-8
pubmed: 18838636
Ann Neurol. 2004 Mar;55(3):306-19
pubmed: 14991808